此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Mechanisms of Early Recurrence in Intracranial Atherosclerotic Disease (MyRIAD)

2021年5月26日 更新者:Jose Romano, MD、University of Miami

The objective of this study is to determine the mechanisms of stroke in patients with Intracranial Atherosclerotic Disease (IAD) by specifically evaluating limitations of antegrade flow through the stenotic artery, distal tissue perfusion to the affected territory, and artery-to-artery embolism. The hypothesis is that non-invasive imaging biomarkers that stratify stroke risk and distinguish mechanisms of IAD. This prospective multicenter study will enroll 175 patients with recently symptomatic high-grade IAD. Patients will be studied within 21 days of the index event (allowing appropriate time to arrange for diverse imaging modalities), with the following advanced neuroimaging techniques to elucidate mechanisms of recurrent ischemia:

  • Quantitative magnetic resonance imaging (QMRA) to assess volumetric flow rate through the stenotic artery.
  • Magnetic resonance perfusion weighted imaging (PWI-MRI) to determine distal tissue perfusion.
  • Vasomotor reactivity by Transcranial Doppler using the breath-holding technique (BHI-TCD) to assess compensatory flow characteristics to the territory distal to the affected artery;
  • Transcranial Doppler with embolic signal monitoring to evaluate artery-to-artery embolism that reflects plaque instability.

Patients will receive standardized medical management and its effectiveness on blood pressure, lipid, and glycemic control will be monitored.

The primary outcome is recurrent stroke in the territory of the stenotic artery during a 1-year follow-up period; secondary outcomes are: a) new asymptomatic ischemic lesions on MRI in the distribution of the stenotic artery at 6-8 weeks, and b) transient ischemic attack (TIA) in the distribution of the stenotic artery during a 1-year follow-up period.

Patients will be recruited at various sites that will be trained and certified on the imaging techniques employed. Raw imaging data will be interpreted centrally.

研究概览

地位

完全的

研究类型

观察性的

注册 (实际的)

105

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Alabama
      • Birmingham、Alabama、美国、35294
        • University of Alabama at Birmingham
    • California
      • Los Angeles、California、美国、90095
        • UCLA
    • Florida
      • Gainesville、Florida、美国、32611
        • University of Florida
      • Jacksonville、Florida、美国、32224
        • Mayo Clinic Jacksonville
      • Miami、Florida、美国、33136
        • University of Miami
    • Illinois
      • Chicago、Illinois、美国、60612
        • Rush University Medical Center
      • Chicago、Illinois、美国、60611
        • Northwestern University Department of Radiology
    • New York
      • New York、New York、美国、10032
        • Columbia University Medical Center
    • South Carolina
      • Charleston、South Carolina、美国、29425
        • Medical University of South Carolina
    • Texas
      • Dallas、Texas、美国、75390
        • The University of Texas Southwestern Medical Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

30年 至 99年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Eligible patients will have a recent stroke or TIA due to intracranial Atherosclerotic Disease (IAD) of 50-99% .

描述

Inclusion Criteria:

  1. Stroke defined as symptoms lasting >24 hours and associated with imaging evidence of acute ischemia in the distribution of the stenotic vessel on CT or MRI.
  2. Eligible TIA defined as transient neurological symptoms lasting <24 hours, need to be:

    1. accompanied by DWI abnormalities in the distribution of the stenotic artery; or
    2. multiple (≥2), stereotyped events associated with unequivocal ischemic symptoms (weakness, aphasia), and attributed to the symptomatic artery.
  3. IAD should involve the intracranial carotid, middle cerebral, intracranial vertebral or basilar arteries.
  4. Stenosis 50-99% quantified by digital subtraction angiography (DSA), CT angiography-CTA or MR angiography-MRA tests. DSA is not required but will be used if obtained as part of clinical care.

    The criteria for 50-99% are:

    1. CTA or DSA: measured 50-99% stenosis by WASID criteria (percent stenosis = (1-[diameter stenosis/diameter normal]) x 100%.
    2. MRA: measured 50-99% stenosis or presence of a flow gap.
  5. Age >30; those 30-49 years of age must also have the presence of established atherosclerotic disease in another vascular bed (coronary, extracranial carotid, peripheral) or the presence of 2 or more risk factors (hypertension, diabetes mellitus, hyperlipidemia, tobacco abuse within the last 2 years).
  6. Enrollment within 21 days of symptom onset and completion of study imaging tests within 21 days of index event (stroke or TIA).
  7. Provide informed consent for participation in the study.

Exclusion Criteria:

  1. Other cause for stroke: atrial fibrillation, acute anterior wall ST-elevation myocardial infarction <30days, mitral stenosis, mechanical valve, intracardiac thrombus or vegetation, dilated cardiomyopathy or ejection fraction <30%, proximal extracranial carotid or vertebral stenosis >50%.
  2. Contraindications to MRI, including MR-incompatible metallic implants, implanted electronic devices, other potentially mobile ferromagnetic material, pregnancy (women in fertile age should have a negative pregnancy test), lactation, morbid obesity, and severe claustrophobia.
  3. Renal impairment defined as either a creatinine level >1.5 mg/dL or a glomerular filtration rate (GFR) <30 mL/min/1.73 m2.
  4. Known allergy to gadolinium.
  5. Unable to obtain informed consent by patient or legally authorized representative.
  6. Severe behavioral or social problems that may interfere with the conduct of the study.
  7. In the investigator's opinion, patient unlikely return for follow up visit and to complete the study.
  8. Participation in a drug or device clinical trial within the last 30 days.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
Intracranial Atherosclerotic Disease, Stroke/TIA
Stroke/TIA due to high grade IAD ≤21 days from symptom onset.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Recurrent stroke in the territory of the symptomatic artery
大体时间:1 year
Time to ischemic stroke in the territory of the symptomatic artery. Stroke is ascertained by the site neurologist and defined as new or worsening symptoms lasting >24 hours and associated with imaging evidence of ischemia on CT or MRI in the distribution of the stenotic artery.
1 year

次要结果测量

结果测量
措施说明
大体时间
TIA in the territory of the stenotic artery
大体时间:1 year
TIA in the territory of the stenotic artery is defined as transient neurological symptoms lasting <24 hours and clearly related to the stenotic artery as per a neurologist.
1 year
Silent infarcts in the distribution of the stenotic artery
大体时间:6-8 weeks
Silent infarcts will be assessed by comparing the DWI and FLAIR sequences at baseline and at 6-8 weeks. Silent infarcts are defined as new discrete lesions not apparent in the baseline images that are in the distribution of the stenotic artery, in the absence of the primary endpoint.
6-8 weeks

其他结果措施

结果测量
措施说明
大体时间
Risk of combined microembolic signals and impaired vasomotor reactivity.
大体时间:1 year
Assess the interaction of the presence of micro embolic signals, assessed by TCD and a marker of plaque emboligenecity, and impaired vasomotor reactivity, assessed by TCD and a marker of collateral flow limitation, in increasing the risk of recurrent stroke in the territory of the target artery.
1 year
Risk of combined poor ante grade flow and poor distal tissue perfusion.
大体时间:1 year
Assess the Interaction between two mechanisms of cerebral ischemia, poor antegrade flow assessed by quantitative MRA as a marker of flow across a stenotic arterial segment, and poor tissue perfusion assessed by perfusion MRI and representative of distal territorial perfusion, in the risk of recurrent stroke in the territory of the stenotic artery.
1 year

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:David S Liebeskind, MD、University of California, Los Angeles
  • 首席研究员:Jose G Romano, MD、University of Miami
  • 首席研究员:Shyam Prabhakaran, MD、University of Chicago

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2015年5月1日

初级完成 (实际的)

2020年7月31日

研究完成 (实际的)

2020年12月31日

研究注册日期

首次提交

2014年4月18日

首先提交符合 QC 标准的

2014年4月21日

首次发布 (估计)

2014年4月23日

研究记录更新

最后更新发布 (实际的)

2021年5月28日

上次提交的符合 QC 标准的更新

2021年5月26日

最后验证

2021年5月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅